Abstract

Objective: To examine the effects of the oral uremic toxin absorbent AST-120 on the concentration of free and protein-bound indoxyl sulphate (IS) and to assess the effects of serum albumin in end-stage kidney disease (ESKD) patients undergoing hemodialysis.
Materials and methods: The study enrolled 37 ESKD patients who initiated hemodialysis at the Shirasagi Hospital. Serum free and bound IS concentrations were measured before the first of 4 hemodialysis sessions and after the last hemodialysis 7 days later. The cohort contained a subgroup of patients in whom AST-120 treatment (6 g/day) was discontinued immediately prior to the first hemodialysis and a subgroup not treated with AST-120. Clinical characteristics were obtained from electronic medical records.
Results: Discontinuation in AST-120 treatment prior to dialysis resulted in marked but highly variable increases in IS concentrations, measured 7 days later, where the efficiency of dialysis of IS was dependent on the serum albumin concentration.
Discussion: The observation that the percentage change in IS concentration was significantly higher after discontinuation of AST-120 compared to those not receiving AST-120 was unexpected as was the finding of a high inter-patient variability in IS concentrations before and after hemodialysis. The effects of a discontinuation in AST-120 administration can be interpreted as a rebound in the systemic absorption of indole precursors, but the source of variability in IS concentrations was unclear. Although there are important limitations in this investigation, the report presents valid and valuable data on free and albumin-bound IS concentrations during hemodialysis and AST-120 treatment as well as measurements of serum albumin concentrations in the group of largely elderly subjects.
Conclusion: AST-120 in ESKD patients has profound effects on the disposition of IS. There are important sources of variability having a possible marked effect on the concentration of IS in patients with chronic kidney disease. Discontinuing AST-120 treatment before hemodialysis, a practice in Japan to avoid the “off-label” administrations of the agent, will result in high and variable concentrations of uremic toxins such as IS. The consequences of this effect will include progression of the disease and the occurrence of cardiovascular and neurological degeneration.

Author Details

Authors

• Takuya Yoshida^{1, 2}
• Masayuki Tsujimoto¹
• Haruno Fujioka¹
• Yuko Irie¹
• Sachiyo Kawakami¹
• Saki Nakatani¹
• Ayako Iso¹
• Ayaka Sugiyama¹
• Mizuho Miyake²
• Kazumi Sumino²
• Rie Tanaka²
• Tomoko Oda²
• Taku Furukubo²
• Satoshi Izumi³
• Tomoyuki Yamakawa⁴
• Tetsuya Minegaki¹
• Kohshi Nishiguchi¹

Departments

• ¹ Department of Clinical Pharmacy, Faculty of Pharmaceutical Science, Kyoto Pharmaceutical University, Kyoto,
• ² Department of Pharmacy Services,
• ³ Department of Medical Technology, and
• ⁴ Department of Medicine, Shirasagi Hospital, Osaka, Japan

Address

Masayuki Tsujimoto
Kyoto Pharmaceutical University
5 Misasagi Nakauchi-cho, Yamashina-ku,
Kyoto 607-8414, Japan
Email: [email protected]

Citation